Understand the physiological basis of the hemostatic system, and discuss both cell-based and cascade models of coagulation
|
|
|
|
|
|
Identify new and emerging therapeutic options in phase 3 for hemophilia and describe their mode of action and physiological role in hemostasis
|
|
|
|
|
|
Comprehend the complexity of balancing the hemostatic system, how clinicians understand and mitigate risk, and what happens with hemostasis if we disturb/re-balance the system with new therapeutic options
|
|
|
|
|
|
Discuss if and how treatment with non-factor therapies can be used, based on patient characteristics
|
|
|
|
|
|
Interpret how the mechanism of action of new therapeutic options impacts the efficacy and safety results in clinical practice, and compare the safety outcomes of new therapies with those generally used in hemophilia patients
|
|
|
|
|
|